Regado Biosciences prices IPO at $4, below revised $5 price

By Renaissance Capital,

Shutterstock photo

Regado Biosciences, which is developing break-through anticoagulant system for cardiovascular surgeries, raised $43 million by offering 10.8 million shares, 2.4 million more than anticipated, at $4, below its lowered $5 price. The company had initially filed to offer 5 million shares at a range of $14 to $16 before cutting the deal size 44% Monday morning. At its $4 offer price, Regado Biosciences commands a market cap of $82 million (63% below its initial proposed market cap) and will have approximately $52 million in cash.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: RGDO

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by